Her2 low (but not negative): the newest biomarker on the block for gastro-oesophageal adenocarcinoma

This study is in line with prevalence data from another recent study that showed HER2 low prevalence is approximately 21% in patient with inoperable or metastatic gastric carcinoma.2 Trastuzumab for HER2 overexpression/ HER2 amplification was one of the first target therapies for solid tumour, and it...
Source: Journal of Clinical Pathology - Category: Pathology Authors: Tags: Editorials Source Type: research